Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...

Viking Therapeutics Inc.'s stock soared 18% Thursday, after the biotech, which is developing a weight-loss drug in pill form that has raised high hopes among analysts and investors, posted earnings ...

Shares of Catalent CTLT lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding ...

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) ...

Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition ...

Novo Nordisk just hit a technical red flag with a Death Cross, but its strong fundamentals suggest a potential rebound.

The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

Novo Nordisk faces growth deceleration but shows promise. Learn more about NVO stock and why its risk/reward profile may ...

Novo Nordisk is among global pharma leaders in the diabetes and weight loss segments. Read why I think NVO stock is a hold.

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...